Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Share this content:

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Sponsor and Collaborators     
Bristol-Myers Squibb

Contact
Usc/Norris Comprehensive Cancer Center     
Los Angeles, California, United States, 90033
Contact: Anthony El-Khoueiry, Site 002            

Texas Oncology     
Dallas, Texas, United States, 75246
Contact: Carlos H. Roberto Becerra, Site 001
            
Scott & White Memorial Hospital And Clinic     
Temple, Texas, United States, 76508
Contact: Lucas Wong, Site 003            

Local Institution     
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site 005            
Canada, Ontario

Local Institution     
Ottawa, Ontario, Canada, K1H 8L6
Contact: Site 004            

Local Institution     
Villejuif Cedex, France, 94800
Contact: Site 006             

Investigator    
Bristol-Myers Squibb

ClinicalTrials.gov Identifier
NCT01046864

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs